|
Volume 15, Issue 5 (September 2013) 15, 586–587; 10.1038/aja.2013.82
Somatic DNA copy number alterations and their potential clinical utility for predicting lethal prostate cancer
Wennuan Liu1,2, Li Wang1,2 and Jianfeng Xu1,2,3
1 Center for Cancer Genomics, Winston-Salem, NC 27157, USA
2 Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
3 Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China
Correspondence: Dr JF Xu, (jxu@wfubmc.edu)
advance online publication, July 1, 2013
| Abstract |
|
Current clinicopathologic indicators are insufficient to distinguish the small percentage of aggressive prostate cancer (PCa) from the vast majority of indolent disease at diagnosis, leading to overtreatment of PCa. A recent study reported and confirmed a strong association of PCa-specific mortality with somatic DNA copy number alterations (CNAs) in primary prostate tumors. If a sensitive, robust and low-cost method can be developed to measure these CNAs in biopsy specimens, it may help to stratify patients for more appropriate management at the time of diagnosis; aggressive treatment or active surveillance for patients with or without these CNAs, respectively.
PDF |
PDF |
|
| |
| Browse: 2948 |
|
